Key words: bezafibrate; blood pressure; cortical blood flow; renal haemodynamics; medullary blood flow; Background. Bezafibrate, a fibric acid analogue, has well-established lipid-and fibrinogen-lowering proper-renal blood flow; SHR; WKY rats ties. Some data exist pointing towards a bloodpressure-lowering effect of bezafibrate. Thus the aim of this study was to examine the acute effect of
also renal function. Recently Fuiano et al. [8] could Circulatory measurements demonstrate that when administering pravastatin to 12
Measurements of MAP (mmHg) were performed via the hypercholesterolaemic patients with nephrotic synarterial catheter with a Statham pressure transducer P23Db drome a significant rise in RBF and GFR occurred.
and Gould Pressure Processor. RBF was measured by a Direct haemodynamic effects affecting GFR have transit-time flow probe (T206, Transonic Systems Inc., also been claimed to result from lovastatin treatment Ithaka, NY ) placed around the left renal artery, carefully [9] . In the study by Stowe et al. [9] a clear-cut effect avoiding disturbance of the renal nerves. This flow probe on GFR occurred, while the rise in renal blood flow permits the measurement of the absolute RBF with a precireached only marginal significance. The authors attrib-sion of ±5%. The probes were precalibrated by the producer. uted the increase in renal blood flow mainly to a CBF ( U/min) was measured by a prism laser flow probe (MBF 3D, Moore Instruments Ltd) placed on the surface preglomerular vasodilatation.
of the left kidney covered with body-warm mineral oil. MBF With a number of lipid-lowering drugs, i.e. different ( U/min) was measured by inserting a needle laser flow probe types of fibrates and miscellaneous statins or combina-3 mm deep (outer medulla) into the left kidney. Both CBF tions of both, improvement of renal function and less and MBF were measured in arbitrary units. All recordings pronounced hypertension has been described in rats were done using a Gould Brush 2600 continuous recorder. [10] [11] [12] [13] [14] [15] [16] . In addition less histological injury and also Validation of the methods has been reported previously [17] . less proteinuria has been observed in models of progressive renal functional impairment.
Experimental procedures These findings support the notion that any of the lipid-lowering drugs exerts a beneficial effect either by In order to investigate the effect of bezafibrate on haemotheir lipid-lowering effect or by a more direct vascular dynamics, we performed a cumulative dose-response study.
effect. Data on direct effects, e.g. following an i.v. After preparation, the rats were infused with a 5% solution administration, are missing.
of human albumin in 0.9% NaCl at a rate of 4 ml/h to Thus the aim of this study was to examine the dose-achieve euvolaemia. Baseline values of MAP, RBF, CBF dependent effects of i.v. bezafibrate application on and MBF were taken for at least 60 min before administering mean arterial pressure (MAP), renal blood flow vehicle or bezafibrate. After reaching steady-state we gave (RBF ), cortical blood flow (CBF ) and medullary i.v. bolus injections over 15 s in 15-min intervals in the following order: vehicle 20 ml and 200 ml followed by blood flow (MBF ) in hypertensive (SHR) and normotbezafibrate 1 mg (20 ml ), 2.5 mg (50 ml ), 5 mg (100 ml ) and ensive ( WKY ) rats. In addition we checked for pos-10 mg (200 ml ). Bezafibrate was dissolved in 0.1 n NaOH sible changes in plasma renin activity (PRA), urine solution (50 g/l ), pH 9.4. volume, and sodium, potassium and protein excretion. 
Subjects and methods
losartan (an AT-1 inhibitor, 1 mg), HOE-140 (a bradykinin antagonist), cyclosporin A (5-12.5 mg), aspirin (50 mg), The experiments were conducted in 12 male SHR and eight ranitidine (2 mg), enalapril (100 mg) and carvedilol (a submale WKY rats (Charles River Deutschland GmbH, Sulzfeld, stance combining b 1 , b 2 and a 1 -blocking properties, 3 mg). Germany). The rats were age-matched (~4 months) weighing The doses of the various compounds were chosen to effec-410-510 g ( WKY ) and 320-400 g (SHR) respectively. All tively block the respective systems [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . animals were kept under controlled environmental conditions regarding temperature (20°C ), humidity (64%), and day--night cycle ( light 6:00 a.m. to 6:00 p.m.). They had free Analytical methods access to tap water and standard rat chow containing 19% protein (Ssniff R/M-H, Ssniff Spezialdiäten GmbH, Soest, The determination of urinary protein was performed by Germany). All experiments were conducted in accordance using the Coomassie method. Urinary sodium and potassium with the NIH Guide for the Care and Use of Laboratory were measured by flame photometry (FLM-3, Radiometer Animals.
Copenhagen, Denmark). PRA was determined by radioimmunoassay as the amount of angiotensin I generated by renin (ng/ml/h) [30] .
Surgical procedures Data calculation and statistics
After anaesthesia with an intraperitoneal injection of thiobutabarbital (InactinA) 100 mg/kg the rats were placed on a For the data evaluation the statistical analysis system SAS was used. The procedures applied are denoted subsequently temperature-regulated surgical table. A rectal thermometer was inserted for monitoring body temperature. Arterial and in capital letters. In the dose response study repeated measures were taken in the same animal. As these data have to venous catheters were inserted into the femoral vessels. The tip of the arterial catheter was placed into the aorta approxi-be compared both with the respective baseline data (withinsubject comparison) and the data of the different rat strains mately 2 mm below the orifice of the left renal artery (for more details see: [17] ).
(between-subject comparison) a repeated measures analysis
Bezafibrate, blood pressure, and renal haemodynamics in SHR and WKY rats 335 of variance was performed (PROC GLM, using in addition the REPEATED statement [31]). Baseline data of the different rat strains were compared by using an unpaired t-test (PROC TTEST [31] ). In these tests a statistical significance was defined as P<0.05. Data are given as means±SEM [32] .
Results

Baseline data
WKY and SHR exhibited no significant differences ( Table 1) with respect to RBF, RVR, CBF, MVR, PRA, urine volume, and body-weight corrected protein, sodium and potassium excretion. Body-weight was lower, while relative kidney weight, MAP, cortical vascular resistance, CBF/100 g body-weight and MBF were significantly higher in SHR than in WKY rats.
Qualitative effect of bezafibrate i.v. application
Bezafibrate administered intravenously resulted in an immediate reduction in MAP and a simultaneous rise in RBF (Figure 1 ). These changes occurred within seconds after the i.v. application. The rapid MAP reduction was followed by a plateau formation (for ficant MAP reduction already at a dose of 1 mg (P= application 0.0328; Table 2 ). No significant differences were found between WKY and SHR (P values ranging from 0.2786 The cumulative doses of bezafibrate induced both in WKY and SHR a dose-dependent stepwise reduction to 0.9545; Table 2 ). Table 2 .
Despite a decreasing blood pressure, RBF increased tion after the first dose of bezafibrate (Table 2) . No further differences in the other parameters analysed in a dose-dependent manner (Figure 2b ). Comparing baseline data with the data obtained with the different were observed ( Table 2) . Protein excretion could not be evaluated by repeated measures analysis of variance doses of bezafibrate revealed a first significant RBF increase already at a dose of 1 mg (P=0.0006; Table 2 ). as intermittently protein determination could not be performed due to a small urine volume. Thus the For the subsequent doses the difference became even more pronounced. Starting with a dose of 2.5 mg the number of samples available for statistical analysis was too small. changes between the strains were significant ( Table 2) with SHR exhibiting a more pronounced increase in RBF than WKY rats.
Effect of vehicle administration Furthermore we observed an increase in CBF starting to be significant with a dose of 5 mg ( Figure 2c) . With respect to baseline data no effect of vehicle administration (20 ml and 200 ml ) on MAP was noted. A strain difference was noted with a dose of 10 mg (P=0.0146; Table 2 ).
Furthermore no differences between the strains could be detected. In contrast RBF increased significantly No effect of bezafibrate on MBF was noted ( Fig. 2d ; Table 2 ).
versus baseline, but no strain difference was noted. The rise in RBF, though statistically significant ( Table 3) , Despite the fall in MAP, PRA decreased significantly both in WKY and SHR after the first dose of bezafibr-is minute in comparison to the absolute values ( Table 1 ) and the changes relative to baseline ate ( Table 2) . Later on no difference with respect to baseline could be noted. Up to the dose of 10 mg the ( Figure 2b) . WKY rats had developed a PRA of 31.3±6.0 (ng/ml/h), while SHR exhibited a value of 11.4±3.1 Administration of possible antagonists (ng/ml/h), the difference being significant ( Table 2) . Marginally significant rises with respect to baseline The effects of bezafibrate (10 mg) on MAP and RBF could not be influenced/blocked by a number of poscould be detected for urine volume and sodium excre- Table 4 . Effect of 10 mg bezafibrate 5 min after the administration Table 2 . Results (P values) of repeated measures analysis of variance (for mean±SEM values see Figure 2 ). In this analysis it was taken of various possible 'antagonists' on MAP and RBF (mean values for 3 SHR each). Data for the effect of 10 mg bezafibrate adminisinto account that repeated measures were taken in the same animal. The dose dependency was tested against the baseline data, while at tered without possible 'antagonists' can be gathered from Figure 2 . the same dose the data were analysed for a difference between the strains. The acute administration of bezafibrate did not blood flow; MBF, medullary blood flow; PRA, plasma renin activity; cause renal functional impairment as indicated by the U volume , urine volume; U Na , urinary sodium excretion; U K , urinary practically unchanged urine volume, and sodium and potassium excretion.
potassium excretion ( Table 2) . As glomerular filtration rate could not be measured in the acute setting of our reduction in renal vascular resistance. The mechanism by which bezafibrate exerts its haemodynamic effects sibly antagonizing substances ( Table 4) . With the remains unclear. Neither the effects of bezafibrate on exception of enalapril (45 min) bezafibrate was admin-MAP nor renal haemodynamics could be blocked by istered 5 min after the injection of the possible 'antag-L-NAME, urodilatin, dopamine, enalapril, haloperionist'. Urodilatin and dopamine had a similar effect dol, bosentan, losartan, HOE-140, cyclosporin A, to bezafibrate. Therefore no bezafibrate application aspirin, ranitidine, or carvedilol. Although the number was performed.
of rats used for the analysis of possible antagonizing drugs was small (n=3/drug) there is no good evidence that the tested drugs/systems might be involved.
Discussion
One could argue that as bezafibrate changes lipid and fibrinogen concentrations [33] , whole blood viscosity might decrease, thus mediating the observed haemoIn this study we could demonstrate that the i.v. administration of bezafibrate causes a rapid dose-dependent dynamic effects. Although we have not measured blood viscosity we would assume that changes in blood reduction in systemic blood pressure paralleled by an acute increase in renal perfusion (RBF and CBF ). The viscosity do not occur within seconds after bezafibrate administration. Also an acute reduction in lipid coneffect on MAP did not differ between the rat strains, but SHR exhibited a more pronounced increase in centration could have had such an effect. Although lipid concentration was not measured in our study, an RBF than Wistar rats. Vehicle injection had no effect on MAP, but caused a statistically significant, though acute effect of bezafibrate can be excluded, as bezafibrate works via the production of proteins relevant for physiologically not relevant, increase in RBF. The lipid metabolism. This process, however takes hours drugs into account one would speculate that the high bezafibrate concentrations following i.v. application to days to occur [33, 34] .
Furthermore one could speculate that, as fibrates resulted in an acute vasodilatation of the pre-and postglomerular vessels in the kidney, resulting in an induce renal cytochrome P-450 fatty acid v-hydroxylase activity [35] , the production of 19-and increase in RBF, while filtration pressure could still be maintained constant. This hypothesis would explain 20-hydroeicosatetraenoic acid (19-and 20-HETE ) increases. As HETEs are assumed to have vasodilatory why in cases of impaired renal autoregulation, as in patients with compromised renal function, a loss of effects, the observed effect might have been HETE mediated. Again this seems not to be probable, as the glomerular filtration rate might occur.
Beside the possible mechanism involved in these observed effects occur within seconds after bezafibrate administration, while effects resulting from an enzyme phenomena the question arises as to why the bloodpressure-lowering effect of lipid-lowering drugs has not induction need at least several minutes to hours to occur.
been reported more frequently in humans. One possible explanation is that this effect has been missed as it is Thus the acute effects of bezafibrate are difficult to explain. On the other hand there are well known, small. Alternatively it could be that the effect had been attributed to other agents like antihypertensive drugs, though more general features of lipid lowering. Vaughan et al. [7] pointed out that by lowering lipids as a considerable number of hyperlipidaemic patients are also treated with antihypertensive drugs. endothelial dysfunction caused by hyperlipidaemia improves. This notion is supported by the findings of In summary, in this study the i.v. application of bezafibrate resulted in profound haemodynamic effects Straznicky et al.
[6 ], who tested blood pressure response to incremental infusions of angiotensin II and with a reduction in blood pressure and an increase in renal perfusion. The exact mechanism underlying these noradrenaline in placebo-and pravastatin-treated patients. Pravastatin caused a significant reduction in effects remains unclear and should be elucidated in further studies. A direct vascular effect, as also noted diastolic blood pressure responses to both angiotensin II and noradrenaline. Further support to with other lipid-lowering drugs, seems possible. If the blood-pressure-lowering effect of bezafibrate is conthis hypothesis is added by Goode and Heagerty [5] who could demonstrate that abnormalities of both firmed in appropriate trials in man, this effect would complement its lipid-and fibrinogen-lowering effects, endothelium-dependent and endothelium-independent relaxation in human peripheral small arteries can be making it an especially suitable drug in patients with a metabolic syndrome. normalized with effective lipid lowering. Thus blood pressure reduction could be due to an improvement in
